LifeMD (LFMD – Research Report) received a Buy rating and an $8.00 price target from B.Riley Financial analyst Marc Wiesenberger today. The company’s shares closed last Friday at $2.11, close to its 52-week low of $1.85.
According to TipRanks.com, Wiesenberger is ranked #737 out of 7883 analysts.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for LifeMD with a $10.00 average price target, implying a 392.6% upside from current levels. In a report issued on May 13, BTIG also maintained a Buy rating on the stock with a $8.00 price target.
The company has a one-year high of $16.28 and a one-year low of $1.85. Currently, LifeMD has an average volume of 131.2K.
Based on the recent corporate insider activity of 34 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of LFMD in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Conversion Labs, Inc. engages in the manufacturing, distribution, and sale of natural immune support products containing proprietary yeast beta glucans. Its products are oral intake tablets and topical creams, and gels for skin application. It operates through the Finished Cosmetic Products and Nutraceutical and Cosmetic Additives segments. The company was founded in 1987 and is headquartered in New York, NY.
Read More on LFMD: